erythromycin has been researched along with quinidine in 51 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (3.92) | 18.7374 |
| 1990's | 7 (13.73) | 18.2507 |
| 2000's | 19 (37.25) | 29.6817 |
| 2010's | 21 (41.18) | 24.3611 |
| 2020's | 2 (3.92) | 2.80 |
| Authors | Studies |
|---|---|
| Cvetkovic, M; Fromm, MF; Kim, RB; Leake, B; Wilkinson, GR | 1 |
| Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA | 1 |
| Fischer, H; Huwyler, J; Poli, S; Schwab, D; Tabatabaei, A | 1 |
| Jolivette, LJ; Ward, KW | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Antes, I; Biemel, K; Hartmann, RW; Marchais-Oberwinkler, S; Müller-Vieira, U; Scherer, C; Voets, M | 1 |
| Abraham, MH; Acree, WE; Ibrahim, A | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Balani, SK; Gan, LS; Li, P; Lu, C | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Giacomini, KM; Huang, Y; Khuri, N; Kido, Y; Kosaka, A; Morrissey, KM; Sali, A; Wittwer, MB; Zhang, X; Zur, AA | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, F; Chen, W; Lan, L; Li, B; Li, J; Liu, Y; Mao, F; Ni, S; Wei, H; Zhu, J | 1 |
| Adebesin, AM; Falck, JR; Fischer, R; Konkel, A; Lossie, J; Paudyal, MP; Puli, N; Schunck, WH; Vijaykumar, J; Wesser, T; Westphal, C; Zhu, C | 1 |
| Guo, HF; Jin, J; Li, ZR; Liu, ZY; Xie, ZS; Xue, ST; Yi, H; Zhang, L | 1 |
| Brown, RD; Feldman, AM | 1 |
| Lemery, R; Nattel, S; Ranger, S; Roy, D; Talajic, M | 1 |
| D'Arcy, PF | 1 |
| Castel, B; Dompmartin, A; Leroy, D; Moreau, A; Remond, B | 1 |
| el-Tahtawy, AA; Jackson, AJ; Ludden, TM | 1 |
| Charland, SL; Cheng, JW; Kindwall, KE; Spinler, SA | 1 |
| Buters, JT; Friedman, FK; Koley, AP; Markowitz, A; Robinson, RC | 1 |
| Brosen, K; Damkier, P; Hansen, LL | 1 |
| Bhoopathy, S; Karnes, HT; Sarkar, MA | 1 |
| Paine, MF; Pusek, SN; Wanwimolruk, S; Watkins, PB | 1 |
| Gundu, J; Machavaram, KK; Yamsani, MR | 1 |
| Fuhr, U; Kober, S; Mutschler, E; Spahn-Langguth, H; Zaigler, M | 1 |
| Dorani, H; Eriksson, UG; Fritsch, H; Hoffmann, KJ; Karlsson, J; Olsson, L; Sarich, TC; Schützer, KM; Wall, U | 1 |
| Hippalgaonkar, K; Majumdar, S; Srirangam, R | 1 |
| Kwatra, D; Mitra, AK; Pal, D; Vadlapatla, RK; Vadlapudi, AD | 1 |
| Avula, B; Hippalgaonkar, K; Khan, IA; Majumdar, S; Srirangam, R | 1 |
| Agrawal, V; Choi, JH; Giacomini, KM; Miller, WL | 1 |
| Kataoka, M; Masaoka, Y; Sakuma, S; Yamashita, S; Yokoyama, T | 1 |
| Di Nardo, G; Ferrero, S; Gilardi, G; Sadeghi, SJ | 1 |
| Li, Z; Reinhart, JM; Tonero, ME | 1 |
2 review(s) available for erythromycin and quinidine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacology of hearing and ototoxicity.
Topics: Adrenal Glands; Aminoglycosides; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Bumetanide; Cochlea; Environmental Pollutants; Erythromycin; Ethacrynic Acid; Female; Furosemide; Guinea Pigs; Hearing; Hearing Disorders; Humans; Kidney; Ovary; Quinidine; Quinine; Seizures; Thyroid Gland | 1978 |
2 trial(s) available for erythromycin and quinidine
| Article | Year |
|---|---|
Comparison of single and multiple dose pharmacokinetics using clinical bioequivalence data and Monte Carlo simulations.
Topics: Adolescent; Adult; Cross-Over Studies; Erythromycin; Humans; Indomethacin; Male; Middle Aged; Monte Carlo Method; Nifedipine; Procainamide; Quinidine; Therapeutic Equivalency | 1994 |
Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4?
Topics: Administration, Oral; Adult; Aged; Antimalarials; Area Under Curve; Breath Tests; Cross-Over Studies; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Erythromycin; Female; Humans; Liver; Male; Metabolic Clearance Rate; Middle Aged; Molecular Probes; Ovarian Neoplasms; Quinidine; Quinine; Troleandomycin | 2002 |
47 other study(ies) available for erythromycin and quinidine
| Article | Year |
|---|---|
OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
Topics: Animals; Anion Transport Proteins; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Caco-2 Cells; Carrier Proteins; Genes, MDR; HeLa Cells; Histamine H1 Antagonists; Humans; LLC-PK1 Cells; Mice; Rats; Swine; Terfenadine; Tissue Distribution; Transfection; Vaccinia virus | 1999 |
Rational use of in vitro P-glycoprotein assays in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera | 2001 |
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cells, Cultured; Drug Evaluation, Preclinical; Fluoresceins; Fluorescent Dyes; Humans; Indicators and Reagents; Mice; Models, Molecular; Rhodamines; Species Specificity; Swine | 2003 |
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Topics: Algorithms; Animals; Dogs; Haplorhini; Humans; Pharmaceutical Preparations; Pharmacokinetics; Rats; Species Specificity; Tissue Distribution | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis.
Topics: Animals; Binding Sites; Cell Line; Cell Membrane Permeability; Cricetinae; Cricetulus; Cytochrome P-450 CYP11B2; Fibrosis; Heart Failure; Humans; Indenes; Models, Molecular; Myocardium; Naphthalenes; Schizosaccharomyces; Structure-Activity Relationship | 2006 |
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
Topics: Air; Animals; Humans; Lung; Organic Chemicals; Probability; Rats; Tissue Distribution; Volatilization | 2008 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A refined cytochrome P540 IC₅₀ shift assay for reliably identifying CYP3A time-dependent inhibitors.
Topics: Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Enzyme Inhibitors; High-Throughput Screening Assays; Humans; Inhibitory Concentration 50; Microsomes, Liver; Time Factors | 2011 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
Topics: Computer Simulation; Fluorescent Dyes; Organic Cation Transport Proteins; Prescription Drugs | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Novel Terminal Bipheny-Based Diapophytoene Desaturases (CrtN) Inhibitors as Anti-MRSA/VISR/LRSA Agents with Reduced hERG Activity.
Topics: Animals; Drug Design; Enzyme Inhibitors; ERG1 Potassium Channel; HEK293 Cells; Hep G2 Cells; Humans; Inhibitory Concentration 50; Methicillin-Resistant Staphylococcus aureus; Mice; Oxidoreductases; Rats; Safety; Solubility; Structure-Activity Relationship; Water | 2018 |
Development of Robust 17(
Topics: Administration, Oral; Animals; Anti-Arrhythmia Agents; Arachidonic Acids; Dose-Response Relationship, Drug; Drug Stability; Epoxide Hydrolases; Esterification; Hepatocytes; Humans; Male; Mice; Microsomes, Liver; Myocardial Infarction; Myocytes, Cardiac; Rats, Sprague-Dawley; Rats, Wistar | 2019 |
Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties.
Topics: Animals; Benzofurans; Bone Morphogenetic Protein 2; Caco-2 Cells; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Mice; Mice, Inbred BALB C; Molecular Structure; Osteoporosis; Ovariectomy; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Thiophenes; Zebrafish | 2020 |
Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism.
Topics: Action Potentials; Aged; Animals; Arrhythmias, Cardiac; Dogs; Electrocardiography; Erythromycin; Humans; In Vitro Techniques; Long QT Syndrome; Male; Purkinje Fibers; Quinidine; Tachycardia | 1990 |
Early reports on drug interactions.
Topics: Acetaminophen; Amiodarone; Apazone; Aspirin; Carbamazepine; Chlordiazepoxide; Cimetidine; Coumarins; Drug Interactions; Erythromycin; Ethanol; Furosemide; Gentamicins; Humans; Levodopa; Lidocaine; Phenytoin; Prenylamine; Quinidine | 1983 |
Drug-induced acute generalized exanthematous pustulosis with positive patch tests.
Topics: Acute Disease; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Drug Eruptions; Erythromycin; Exanthema; Female; Humans; Middle Aged; Patch Tests; Quinidine; Skin Diseases, Vesiculobullous; Spiramycin | 1995 |
Possible inhibition of hepatic metabolism of quinidine by erythromycin.
Topics: Aged; Cytochrome P-450 Enzyme System; Drug Interactions; Electrocardiography; Erythromycin; Humans; Liver; Male; Metabolic Clearance Rate; Quinidine | 1995 |
CO binding kinetics of human cytochrome P450 3A4. Specific interaction of substrates with kinetically distinguishable conformers.
Topics: Animals; Carbon Monoxide; Cimetidine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Erythromycin; Ethinyl Estradiol; Humans; Kinetics; Mixed Function Oxygenases; Nifedipine; Protein Binding; Quinidine; Recombinant Proteins; Spodoptera; Substrate Specificity; Testosterone; Time Factors; Transfection; Warfarin | 1995 |
Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Beverages; Citrus; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diclofenac; Disulfiram; Drug Interactions; Enzyme Inhibitors; Erythromycin; Humans; Itraconazole; Male; Mixed Function Oxygenases; Oxidation-Reduction; Quinidine; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases | 1999 |
Characterization of quinidine 3-hydroxylation as a probe for the CYP 3A enzyme using a novel capillary electrophoresis technique.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Biomarkers; Cytochrome P-450 CYP3A; Electrophoresis, Capillary; Enzyme Inhibitors; Erythromycin; Fluconazole; Hydroxylation; Ketoconazole; Microsomes, Liver; Oxidoreductases, N-Demethylating; Quinidine; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Stereoisomerism | 2002 |
Effect of various cytochrome P450 3A and P-glycoprotein modulators on the biliary clearance of bromosulphaphthalein in male wistar rats.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bile; Butyrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Doxorubicin; Enzyme Induction; Enzyme Inhibitors; Erythromycin; Etoposide; Indinavir; Infusions, Intravenous; Isoenzymes; Ketoconazole; Male; Nitrendipine; Quinidine; Rats; Rats, Wistar; Rifampin; Sulfobromophthalein | 2004 |
Rate-limiting biotransformation of triamterene is mediated by CYP1A2.
Topics: Caffeine; Chromatography, High Pressure Liquid; Coumarins; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Dose-Response Relationship, Drug; Enzyme Inhibitors; Erythromycin; Humans; Hydroxylation; Ketoconazole; Kinetics; Microsomes, Liver; Omeprazole; Quinidine; Substrate Specificity; Sulfuric Acid Esters; Theophylline; Triamterene | 2005 |
Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein-mediated excretion.
Topics: Adult; Animals; Anti-Bacterial Agents; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azetidines; Benzylamines; Bile; Biological Transport, Active; Caco-2 Cells; Calcium Channel Blockers; Cell Line; Dogs; Dose-Response Relationship, Drug; Drug Interactions; Erythromycin; Female; Humans; In Vitro Techniques; Male; Partial Thromboplastin Time; Quinidine; Rats; Rats, Sprague-Dawley; Verapamil | 2006 |
Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators.
Topics: Administration, Topical; Animals; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biotransformation; Drug Interactions; Erythromycin; Fluorescein; Fluorescent Dyes; Half-Life; Male; Metabolic Clearance Rate; Ophthalmic Solutions; Prednisolone; Quinidine; Rabbits; Tissue Distribution; Verapamil; Vitreous Body | 2009 |
Interaction of gatifloxacin with efflux transporters: a possible mechanism for drug resistance.
Topics: Adenosine; Adenosine Triphosphate; Animals; Anti-Bacterial Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzimidazoles; Binding, Competitive; Biological Transport; Cell Line; Cell Polarity; Diketopiperazines; Dogs; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Erythromycin; Fluoroquinolones; Gatifloxacin; Heterocyclic Compounds, 4 or More Rings; Humans; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Propionates; Quinidine; Quinolines; Transfection | 2010 |
Interaction between topically and systemically coadministered P-glycoprotein substrates/inhibitors: effect on vitreal kinetics.
Topics: Administration, Topical; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Interactions; Erythromycin; Injections, Intravenous; Male; Mass Spectrometry; Microdialysis; Ophthalmic Solutions; Prednisolone; Quinidine; Rabbits; Substrate Specificity; Time Factors; Tissue Distribution; Verapamil; Vitreous Body | 2010 |
Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase.
Topics: Biocatalysis; Cytochrome P-450 CYP3A; Erythromycin; Genetic Variation; Humans; Kinetics; Midazolam; Mutant Proteins; NADPH-Ferrihemoprotein Reductase; Polymorphism, Single Nucleotide; Quinidine; Substrate Specificity; Testosterone | 2010 |
Estimation of P-glycoprotein-mediated efflux in the oral absorption of P-gp substrate drugs from simultaneous analysis of drug dissolution and permeation.
Topics: Algorithms; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Drug Interactions; Erythromycin; Gene Expression; Glycerol; Humans; Intestinal Absorption; Loperamide; Models, Biological; Pharmaceutical Preparations; Propanolamines; Puromycin; Quinidine; Saquinavir; Solubility; Surface-Active Agents; Terfenadine; Verapamil; Vinblastine | 2011 |
Drug-drug interactions and cooperative effects detected in electrochemically driven human cytochrome P450 3A4.
Topics: Cimetidine; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Diclofenac; Drug Interactions; Electrochemical Techniques; Electrodes; Enzyme Inhibitors; Enzymes, Immobilized; Erythromycin; Inhibitory Concentration 50; Ketoconazole; Polyethylenes; Quaternary Ammonium Compounds; Quinidine | 2012 |
Cytochrome P450 reaction phenotyping of itraconazole hydroxylation in the dog.
Topics: Animals; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dogs; Enzyme Inhibitors; Erythromycin; Hydroxylation; Itraconazole; Microsomes, Liver; Quinidine | 2022 |